JP2023052201A5 - - Google Patents

Download PDF

Info

Publication number
JP2023052201A5
JP2023052201A5 JP2023000295A JP2023000295A JP2023052201A5 JP 2023052201 A5 JP2023052201 A5 JP 2023052201A5 JP 2023000295 A JP2023000295 A JP 2023000295A JP 2023000295 A JP2023000295 A JP 2023000295A JP 2023052201 A5 JP2023052201 A5 JP 2023052201A5
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023000295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023052201A (ja
JP7812813B2 (ja
Filing date
Publication date
Priority claimed from JP2018516828A external-priority patent/JP7411326B2/ja
Application filed filed Critical
Publication of JP2023052201A publication Critical patent/JP2023052201A/ja
Publication of JP2023052201A5 publication Critical patent/JP2023052201A5/ja
Priority to JP2026012737A priority Critical patent/JP2026090316A/ja
Application granted granted Critical
Publication of JP7812813B2 publication Critical patent/JP7812813B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023000295A 2015-10-01 2023-01-04 タンパク質－タンパク質インターフェースを分析するための方法および試薬 Active JP7812813B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026012737A JP2026090316A (ja) 2015-10-01 2026-01-29 タンパク質－タンパク質インターフェースを分析するための方法および試薬

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562235896P 2015-10-01 2015-10-01
US62/235,896 2015-10-01
JP2018516828A JP7411326B2 (ja) 2015-10-01 2016-09-30 タンパク質－タンパク質インターフェースを分析するための方法および試薬
PCT/US2016/054691 WO2017059207A1 (en) 2015-10-01 2016-09-30 Methods and reagents for analyzing protein-protein interfaces

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018516828A Division JP7411326B2 (ja) 2015-10-01 2016-09-30 タンパク質－タンパク質インターフェースを分析するための方法および試薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026012737A Division JP2026090316A (ja) 2015-10-01 2026-01-29 タンパク質－タンパク質インターフェースを分析するための方法および試薬

Publications (3)

Publication Number Publication Date
JP2023052201A JP2023052201A (ja) 2023-04-11
JP2023052201A5 true JP2023052201A5 (enExample) 2023-06-14
JP7812813B2 JP7812813B2 (ja) 2026-02-10

Family

ID=58427956

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018516828A Active JP7411326B2 (ja) 2015-10-01 2016-09-30 タンパク質－タンパク質インターフェースを分析するための方法および試薬
JP2023000295A Active JP7812813B2 (ja) 2015-10-01 2023-01-04 タンパク質－タンパク質インターフェースを分析するための方法および試薬
JP2026012737A Pending JP2026090316A (ja) 2015-10-01 2026-01-29 タンパク質－タンパク質インターフェースを分析するための方法および試薬

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018516828A Active JP7411326B2 (ja) 2015-10-01 2016-09-30 タンパク質－タンパク質インターフェースを分析するための方法および試薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026012737A Pending JP2026090316A (ja) 2015-10-01 2026-01-29 タンパク質－タンパク質インターフェースを分析するための方法および試薬

Country Status (6)

Country Link
US (5) US9989535B2 (enExample)
EP (2) EP4242304A3 (enExample)
JP (3) JP7411326B2 (enExample)
AU (3) AU2016329064B2 (enExample)
CA (1) CA3000822A1 (enExample)
WO (1) WO2017059207A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
WO2016112295A1 (en) 2015-01-09 2016-07-14 Warp Drive Bio, Inc. Compounds that participate in cooperative binding and uses thereof
CA3000822A1 (en) 2015-10-01 2017-04-06 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
CN108697729B (zh) 2016-02-04 2023-05-09 约翰霍普金斯大学 新型GLUT抑制剂rapaglutin及其用途
AU2017214557B2 (en) 2016-02-04 2022-05-19 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
CA3020594A1 (en) 2016-04-12 2017-10-19 Warp Drive Bio, Inc. Compositions and methods for the production of compounds
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
US20200199102A1 (en) * 2017-04-05 2020-06-25 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
WO2018187423A1 (en) * 2017-04-05 2018-10-11 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
JP7472026B2 (ja) * 2018-02-23 2024-04-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 選択的なタンパク質分解を誘導するための低分子およびその使用法
US12678067B1 (en) 2019-03-20 2026-07-14 Biological Art Group, Inc. Telemetry implants
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CN121471132A (zh) 2019-11-04 2026-02-06 锐新医药公司 Ras抑制剂
US20250388598A1 (en) * 2019-11-04 2025-12-25 Revolution Medicines, Inc. Ras inhibitors
JP7461078B2 (ja) 2019-11-08 2024-04-03 ナノテンパー・テクノロジーズ・ゲーエムベーハー 溶液中の粒子の特徴付け
CN111118046B (zh) * 2020-01-16 2022-02-22 中国人民解放军军事科学院军事医学研究院 一种能够调控MSCs成脂肪分化能力的基因及其衍生产品
GB202007106D0 (en) * 2020-05-14 2020-07-01 Ucl Business Plc Cyclosporine analogues
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN119661684B (zh) * 2024-10-21 2025-11-25 山东大学 一种高抗炎活性的脂联素突变体及其制备方法与应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE92501T1 (de) 1984-10-04 1993-08-15 Sandoz Ag Monoklonale antikoerper gegen zyklosporine.
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
ATE113606T1 (de) 1989-04-15 1994-11-15 Nippon Chemiphar Co Peptide und diese peptide enthaltende wirkstoffe gegen dementia.
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
ES2089723T3 (es) 1992-03-27 1996-10-01 American Home Prod 29-demetoxirapamicina para inducir la inmunodepresion.
WO1995008548A1 (en) 1993-09-20 1995-03-30 The Leland Stanford Junior University Recombinant production of novel polyketides
IL112873A (en) 1994-03-08 2005-03-20 Wyeth Corp Rapamycin-fkbp12 binding proteins, their isolation and their use
GB9410142D0 (en) 1994-05-20 1994-07-06 Univ Warwick Carbapenems
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
SE9603465D0 (sv) 1996-09-23 1996-09-23 Astra Ab New compounds
US6902913B2 (en) 1997-04-30 2005-06-07 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
US6153383A (en) 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
US6372712B1 (en) 1998-05-22 2002-04-16 The Board Of Trustees Of The Leland Stanford Jr. University Synthetic bifunctional molecules containing a drug moiety and presenter protein ligand
EP1117801B1 (en) 1998-10-02 2006-11-29 Kosan Biosciences, Inc. Polyketide synthase enzymes and recombinant dna constructs therefor, for the production of compounds related to fk-506 and fk-520
US6686454B1 (en) * 1998-10-09 2004-02-03 Isotechnika, Inc. Antibodies to specific regions of cyclosporine related compounds
GB9927191D0 (en) 1999-11-17 2000-01-12 Angeletti P Ist Richerche Bio Methods and means for regulation of gene expression
AU1776501A (en) 1999-11-19 2001-05-30 Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
US7220552B1 (en) * 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
NZ516918A (en) * 2000-05-23 2004-06-25 Vertex Pharma Caspase inhibitors and uses thereof
US7176037B2 (en) 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
WO2003014311A2 (en) 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Methods for altering polyketide synthase genes
US6809077B2 (en) * 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
US6987090B2 (en) 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
AU2003284984B2 (en) * 2002-10-30 2008-10-23 Merck Sharp & Dohme Corp. Gamma-aminoamide modulators of chemokine receptor activity
US7012065B2 (en) * 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
CA2643826A1 (en) 2006-02-27 2008-06-12 Paul A. Wender Compositions and methods for transport of molecules with enhanced release properties across biological barriers
US20070203168A1 (en) 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same
US7601852B2 (en) 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
GB0805363D0 (en) 2008-03-20 2008-04-30 Sinvent As Novel NRPS-PKS gene cluster and its manipulation and utility
WO2010031185A1 (en) 2008-09-19 2010-03-25 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
JP5789190B2 (ja) 2008-09-24 2015-10-07 シャンハイ インスティテュート オブ オーガニック ケミストリー，チャイニーズ アカデミー オブ サイエンシズ 新規の遺伝子クラスター
RU2492181C2 (ru) 2009-01-30 2013-09-10 Энанта Фармасьютикалс, Инк. Аналоги циклоспорина для предупреждения или лечения инфекции гепатита с
WO2011008260A2 (en) * 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
EP2456777A2 (en) 2009-07-24 2012-05-30 Université Henri Poincaré - Nancy 1 Stambomycin and derivatives, their production and their use as drugs
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP5174971B2 (ja) 2009-10-22 2013-04-03 ペプチドリーム株式会社 ペプチド翻訳合成におけるｒａｐｉｄディスプレイ法
AU2011336727B2 (en) 2010-11-30 2016-11-03 The Johns Hopkins University Hybrid cyclic libraries and screens thereof
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
AU2012257513B2 (en) 2011-05-19 2017-05-11 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Macrocyclic compounds as protein kinase inhibitors
US9260484B2 (en) 2011-06-15 2016-02-16 Ohio State Innovation Foundation Small molecule composite surfaces as inhibitors of protein-protein interactions
DE102011111991A1 (de) * 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
US8987456B2 (en) * 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
PL2872157T3 (pl) 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
EP2806274A1 (en) 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
US10233431B2 (en) 2014-02-26 2019-03-19 The Regents Of The University Of California Producing 3-hydroxycarboxylic acid and ketone using polyketide synthases
CN106255882A (zh) 2014-03-03 2016-12-21 耶路撒冷希伯来大学伊森姆研究发展公司 用于检测铜绿假单胞菌的方法和装置
WO2016112295A1 (en) 2015-01-09 2016-07-14 Warp Drive Bio, Inc. Compounds that participate in cooperative binding and uses thereof
TW201629069A (zh) 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
EP3277704A1 (en) * 2015-03-31 2018-02-07 Allergan, Inc. Cyclosporins modified on the mebmt sidechain by heterocyclic rings
CA3000822A1 (en) 2015-10-01 2017-04-06 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
CN110506120A (zh) 2016-10-28 2019-11-26 银杏生物制品公司 用于生产化合物的组合物和方法

Similar Documents

Publication Publication Date Title
US20240122925A1 (en) Shp2 phosphatase inhibitors and methods of making and using the same
JP2020520988A5 (enExample)
JP2019501863A5 (enExample)
US6492408B1 (en) Small molecules useful in the treatment of inflammatory disease
ES2306665T3 (es) Pequeñas moleculas utiles en el tratamiento de la enfermedad inflamatoria.
TW294650B (enExample)
JP5178513B2 (ja) 金属錯体を介しての治療化合物の細胞ターゲティング装置への結合方法
EP1369132A1 (en) Oxaliplatin containing liposome preparation
US7635463B2 (en) Compositions for delivery of therapeutics and other materials
JP2005500266A5 (enExample)
JP2022541749A (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
JP2015518832A5 (enExample)
JP2022093718A5 (enExample)
RU2218337C2 (ru) Производные тиазола, способ их получения и фармацевтическая композиция на их основе
Denmark et al. Configuration, conformation, and colligative properties of a phosphorus-stabilized anion
CN105473169A (zh) 改性聚芳醚酮(paek)聚合物及其获得方法
EP1535903A1 (en) Modified MscL protein channel
CN111971060A (zh) 募集抗体并靶向肿瘤细胞的双功能分子
JP2010518158A5 (enExample)
Gallagher et al. Electrochemical anion recognition by redox-responsive unnatural amino acid derivatives; the X-ray crystal structure of N-ferrocenoyl glycine methyl ester,(η5-C5H5) Fe (η5-C5H4) CONHCH2COOMe
JP2013509396A5 (enExample)
JP5078987B2 (ja) 遺伝子導入活性を有する新規なインテグリン結合ｒｇｄリポペプチド
Licen et al. Artificial anion transporters in bilayer membranes
CN101326191B (zh) 膦过渡金属配合物、其制造方法和含有该配合物的抗癌剂
CN116333086A (zh) 一种寡肽环肽及其应用